Table 2.

Dichotomous Scoring Used Across Antibodies for PD-L1 IHC Tests in Lung Cancer

Antibody (developer) [drug against which the study validated the test]	Cutoff/Threshold
22C3 (Dako) [pembrolizumab]	1% (used in training group): 1 study [4]a 50% (determined as optimal cutoff): 1 study [4]a
28–8 (Dako) [nivolumab]	1%: 3 studies [7, 10, 12]a 5%: 2 studies [10, 11]a 10%: 1 study [10]a 50%: 1 study [11]a
SP263 (Roche) [durvalumab]	25%: 3 studies [7, 14, 28]a,b
SP142 (Roche) [atezolizumab]	1%: 2 studies [19, 20]a 5%: 2 studies [19, 20]a,c 50%: 1 study [20]a
E1L3N (Cell Signaling Technology; reagent provider) [not applicable]	1%: 2 studies [20, 21]a 5%: 4 studies [11, 20, 21, 23]a,c 50%: 3 studies [11, 20, 21]a

^aTested in tumor cells. ^b Tested in tumor-infiltrating immune cells. ^c Tested in tumor stroma